Intuitive Surgical’s Impressive Q2 Earnings Can’t Offset US Slowdown and Unchanged Guidance

Intuitive Surgical shares hit 52-week low after 14.2% plunge despite beating Q2 earnings, as cautious guidance, US slowdown, and recall weigh on outlook.

Intuitive Surgical’s stock suffered its worst single-day beating in months on Friday, tumbling 14.2% to close at €302.00 in Frankfurt — a fresh 52-week low that leaves the shares 41.5% below January’s high of €516.50. The sell-off came despite a quarterly earnings report that comfortably beat analyst expectations, underscoring how a downbeat outlook can outweigh even the strongest operational numbers.

Solid second-quarter headline numbers

The robotic-surgery pioneer posted second-quarter revenue of $2.89 billion, a 19% increase year-on-year and ahead of the $2.82 billion consensus. Adjusted earnings per share clocked in at $2.80, well above the $2.51 that analysts had penciled in. Global procedures using its da Vinci and Ion systems rose roughly 16%, while the company placed 246 of its newest da Vinci 5 systems during the quarter. Its installed base now stands at 11,710 da Vinci units, up 12% from a year ago.

With cash and investments totalling $8.63 billion and no traditional debt, the balance sheet remains exceptionally strong. Yet none of that was enough to prevent a rout.

The guidance that disappointed

The problem lay squarely in the forward-looking numbers. Management kept its full-year procedure-growth guidance unchanged at 13.5% to 15.5% — and signalled that the actual outcome would likely land near the 14.5% midpoint. For investors who had hoped for an upgrade after the strong first half, that was a bitter disappointment, especially given that global procedure growth hit 16% in the second quarter alone. The implied deceleration in the second half caught many off guard.

US slowdown is the main culprit

The brakes are coming from Intuitive’s largest market. US da Vinci procedure growth slowed to 12% in the second quarter, down from 14% in the first quarter. CEO Dave Rosa pointed to changes in patient insurance coverage: expiring subsidies and tax credits under the Affordable Care Act have left more Americans without insurance, prompting them to postpone elective, non-urgent surgeries.

That headwind is compounded by a tough competitive environment in China, where local rivals and politically driven pricing pressure are weighing on public tenders. What is more, the growing use of GLP-1 weight-loss drugs is eating into bariatric surgery volumes, which fell in the high single-digit percentage range during the quarter.

Recall and margin pressure add to the gloom

A separate overhang comes from a Class II voluntary recall involving 454 components related to an e-brake holder pin on the da Vinci system. The defect was discovered early in 2025 and keeps regulatory and quality-control risks firmly on investors’ radar.

Meanwhile, the ramp-up of the da Vinci 5 platform, while showing healthy adoption rates, is putting near-term pressure on margins. Intuitive sees full-year adjusted gross margin in the range of 68.0% to 69.0%, weighed down by tariffs and the costs of the production build-out for the new platform.

Analysts trim targets but stay constructive

Several Wall Street houses responded to the cautious tone by cutting their price targets. Mizuho lowered its to $400, while Stifel trimmed its more aggressively from $670 to $550. Brokerages including JPMorgan and Citigroup are also said to have reduced their valuations in reaction to the growth deceleration and ACA uncertainty. Most analysts, however, maintained their positive ratings, arguing that Intuitive’s market leadership and robust financials remain intact.

From a technical perspective, the stock’s relative strength index has fallen to 29.9, deep in oversold territory — a level that often presages a short-term bounce. The shares now trade about 16% below their 50-day moving average and roughly 28% below the 200-day line. Whether the €302.00 mark can hold as a floor will depend in part on whether other medical-technology companies confirm the ACA-driven weakness when they report, or whether this is a phenomenon specific to Intuitive’s procedure mix.